A Singular Genetic Flaw in Aggressive Blood Cancer
Researchers at Goethe University Frankfurt have identified a unique genetic vulnerability in acute myeloid leukemia cells that spares healthy blood stem cells during laboratory tests. According to a study led by Jan-Henning Klusmann and Dirk Heckl, deactivating a specific gene locus called MYNRL15 caused cancer cells to lose their ability to replicate and subsequently die off.
Mapping Noncoding RNAs in Pediatric Cases
Acute myeloid leukemia is an aggressive blood cancer characterized by the degeneration of early-stage blood stem cells and precursor cells. According to Goethe University Frankfurt researchers, the disease accounts for about four percent of childhood and adolescent malignancies, with only half of affected patients surviving without a relapse under intensive chemotherapy. To find more specific treatments that avoid the severe side effects of non-specific chemotherapy, the Frankfurt team cataloged noncoding RNAs—molecules that regulate cell growth and division without producing proteins—in leukemia cells taken from sick children.
The Discovery of the MYNRL15 Locus
The comparative inventory revealed that leukemia cells differentially expressed nearly 500 noncoding RNAs compared to healthy blood stem cells. When the research team systematically turned off each of these RNA-associated genes, one specific gene stood out. According to the study findings, deactivating the MYNRL15 gene caused AML cancer cells to lose their indefinite replication capacity and die.
Disrupting Chromatin Architecture to Stop Leukemia
The Frankfurt team discovered that the lethal effect on cancer cells stemmed directly from the MYNRL15 gene itself rather than the absence of noncoding RNA products. According to Klusmann, destroying the gene altered the three-dimensional spatial organization of the cell’s chromatin. This structural shift deactivated essential survival genes required by the AML cancer cells.
Broad Implications Across Patient Cell Lines
Laboratory tests confirmed that this inhibitory mechanism functioned across various AML cell lines, encompassing samples from both children and adults. The tested lines included common disease subtypes, such as those frequently observed in patients with Down syndrome. Because every leukemia cell line studied relied on this specific gene locus, researchers are now exploring whether this dependence can serve as a foundation for targeted gene therapies.
Worth a look